Aminobenzoic acids and derivatives
Apexbio Technology LLC Nafamostat 81525-10-2 50mg
Nafamostat (CAS 81525-10-2) is a small-molecule inhibitor targeting a broad spectrum of serine proteases including thrombin plasmin kallikrein and human trypsin It is designed to block protease-mediated hydrolysis reactions thereby regulating coagulation pathways and inflammation-related protease activity Nafamostat exerts its biological activity primarily through reversible binding to protease active sites inhibiting their enzymatic functions In biochemical assays Nafamostat demonstrates potent inhibitory activity with an IC50 value of approximately 1 10 nM against human trypsin Based on these pharmacological properties Nafamostat holds research potential in coagulation pathway studies inflammation-related protease research pancreatitis modeling and mechanistic investigations of blood coagulation disorders and inflammatory responses
Apexbio Technology LLC LENVATINIB-MESYLATE-25MG
lenvatinib Mesylate (CAS No 857890-39-2) is an oral tyrosine kinase inhibitor researched extensively in oncology Originating as a synthetic compound its mechanism of action involves targeting multiple receptor tyrosine kinases (RTKs) associated with tumor growth angiogenesis and progression These include VEGFR FGFR and PDGFR pathways In vitro lenvatinib Mesylate demonstrates activity in the nanomolar to low micromolar range indicating its potency It is widely applied in various cancer cell models and animal studies for testing therapeutic efficacy and understanding tumor biology Lenatatinib Mesylate is also used in drug screening programs to identify its effects and potential combinations with other therapies Experimental concentrations typically depend on the specific research design
eMolecules 82956-11-4 | Nafamostat mesylate | Combi-Blocks, Inc. | MFCD00941430 | 539.580 | C21H25N5O8S2 | 98.000 | CS(O)(=O)=O.CS(O)(=O)=O.NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N | 1g | 586079372
Nafamostat mesylate | Combi-Blocks, Inc. | 82956-11-4 | MFCD00941430 | 539.580 | C21H25N5O8S2 | 98.000 | CS(O)(=O)=O.CS(O)(=O)=O.NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N | 1g | 586079372
Apexbio Technology LLC Pefloxacin Mesylate 70458-95-6 10mM (in 1mL DMSO)
Pefloxacin Mesylate (CAS 70458-95-6) is a small-molecule inhibitor targeting bacterial DNA gyrase (topoisomerase II) It is designed to inhibit bacterial DNA gyrase activity thereby interfering with DNA replication and transcription Pefloxacin Mesylate exerts its biological activity primarily through inhibition of DNA gyrase In biochemical research assays Pefloxacin Mesylate demonstrates inhibitory activity with IC50 values in vitro in the low micromolar range depending on bacterial species and assay conditions Based on these pharmacological properties Pefloxacin Mesylate holds research potential in microbiological assays antimicrobial susceptibility tests and studies of bacterial enzyme inhibition
![Medchemexpress LLC 2-(4-(1-(quinolin-6-ylmethyl)-1H-triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol | 956906-93-7 | ≥98.0% | 50 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000233428.png-250.jpg)
Medchemexpress LLC 2-(4-(1-(quinolin-6-ylmethyl)-1H-triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol | 956906-93-7 | ≥98.0% | 50 MG
PF-04217903 mesylate is the methanesulfonate salt of a selective ATP-competitive c-Met (MET) tyrosine kinase inhibitor used as a research reagent for preclinical studies. It is supplied as a solid salt form for biochemical and cell-based assays to evaluate c-Met signaling and inhibitor activity.
- Selective ATP-competitive c-Met inhibitor for research applications.
- Mesylate salt form to improve solubility and handling.
- Typical purity ≥98.0% by HPLC.
- Molecular weight 468.49 g/mol.
- Intended for biochemical kinase assays and cell-based studies.
TARGETMOL CHEMICALS INC TIRILAZAD MESYLATE 5MG
Also available in 50mg 100mg and bulk. Please contact Fisher for quotes. Tirilazad mesylate (U 74006F) is a non-glucocorticoid lipid peroxidation inhibitor with antiviral activity and neuroprotective activity.Tirilazad mesylate confines intracellular intramembranous foci attenuates spinal cord injury induced by trauma stroke and ischemia/reperfusion injuries inhibits toxins in dogs reduces the effects of Tirilazad mesylate is used in the study of neurological disorders. purity: 99%
Medchemexpress LLC Lazertinib (mesylate) | 2247995-37-3 | 99.85% | 650.75 | 1 ML
Lazertinib mesylate is a potent, selective, CNS-penetrant, orally available, and irreversible EGFR tyrosine kinase inhibitor. It shows high selectivity for activating (EGFRm) and T790M resistance mutations, inhibiting phosphorylation of EGFR, AKT, and ERK. This leads to apoptosis and suppression of tumor growth, making it suitable for the study of non-small cell lung cancer.
- Potent, selective, CNS-penetrant, orally available, and irreversible EGFR tyrosine kinase inhibitor.
- Shows high selectivity for activating (EGFRm) and T790M resistance mutations.
- Inhibits phosphorylation of EGFR, AKT, and ERK.
- Leads to apoptosis and suppression of tumor growth.
- Suitable for the study of non-small cell lung cancer.
Chemscene Tris(4-methoxy-3 5-dimethylphenyl)phosphine | 1g | CS-W014454 | 96% | 121898-64-4 | MFCD03840342 | 436 53 | C27H33O3P
Chemscene | Tris(4-methoxy-3 5-dimethylphenyl)phosphine | 1g | CS-W014454 | 96% | 121898-64-4 | MFCD03840342 | 436 53 | C27H33O3P